* TRACON Pharmaceuticals Inc reported a quarterly adjusted loss of $1.33 per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-7.20. The mean expectation of two analysts for the quarter was for a loss of $1.19 per share. Wall Street expected results to range from $-1.20 to $-1.18 per share.
* Revenue was $100.00 thousand; analysts expected zero.
* TRACON Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.33.
* The company reported a quarterly loss of $3.17 million.
* TRACON Pharmaceuticals Inc shares had fallen by 76.5% this quarter and lost 42.3% so far this year.
FORECAST CHANGES
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for TRACON Pharmaceuticals Inc is $37.50 This summary was machine generated from LSEG data May 14 at 09:22 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.19 -1.33 Missed
Dec. 31 2023 -1.60 0.20 Beat
Sep. 30 2023 -1.30 5.80 Beat
Jun. 30 2023 -2.00 4.40 Beat
Comments